Phase III Trial of Tislelizumab and Lenvatinib in Unresectable Intrahepatic Cholangiocarcinoma
A Phase III trial is underway to compare the efficacy of TACE plus tislelizumab and lenvatinib against GEMCIS plus tislelizumab in patients with unresectable intrahepatic cholangiocarcinoma.